New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BSX;HUM;AGP;UNH;WCG;MDT;HS;WLP;MOH;CI;STJ;AET;CNC;CVH;HNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 28, 2015
06:02 EDTAETAetna reports Q1 operating EPS $2.39, consensus $1.95
Subscribe for More Information
05:51 EDTBSXBoston Scientific drug Eluvia trial meets primary endpoint
Subscribe for More Information
April 27, 2015
16:23 EDTBSXBoston Scientific announces strategic collaboration with Brainlab AG
Subscribe for More Information
15:35 EDTMDTMedtronic announces consent decree with FDA for Synchromed system
Subscribe for More Information
15:31 EDTMDTFDA enters consent decree with Medtronic
The FDA announced the filing of a consent decree against Medtronic and two of the company’s officers—S. Omar Ishrak and Thomas Tefft —for repeatedly failing to correct violations, related to the manufacture of Synchromed II Implantable Infusion Pump Systems, medical devices that deliver medication to treat primary or metastatic cancer, chronic pain and severe spasticity. These violations occurred at the company’s Neuromodulation facilities in Columbia Heights, Minnesota, where the devices are manufactured. The legal action requires the company to stop manufacturing, designing and distributing new Synchromed II Implantable Infusion Pump Systems except in very limited cases, such as when a physician determines that the Synchromed II Implantable Infusion Pump System is medically necessary for a patient’s treatment. The consent decree also requires Medtronic to retain a third-party expert to help develop and submit plans to the FDA to correct violations. The consent decree will remain in effect until the FDA has determined that Medtronic has met all the provisions listed in the consent decree.
15:04 EDTBSX, AET, CNCNotable companies reporting before tomorrow's open
Subscribe for More Information
13:27 EDTAETAetna technical comments ahead of earnings
Subscribe for More Information
13:15 EDTAETEarnings Watch: Aetna to report Q1 results amid continued membership growth
Aetna (AET) is scheduled to report first quarter earnings before the market open on Tuesday, April 28 with a conference call scheduled for 8:00 am ET. Aetna operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. EXPECTATIONS: Analysts are looking for earnings per share of $1.95 on revenue of $15.46B, according to First Call. The consensus range for EPS is $1.87-$2.13 on revenue of $15.08B-$16.0B. LAST QUARTER: Aetna reported fourth quarter EPS of $1.22, which was in-line with consensus estimates, on revenue of $14.77B against estimates of $14.6B. The company raised its fiscal 2015 EPS view to at least $7.00, against consensus estimates at the time of $7.16. "Aetna achieved record annual operating revenue and operating earnings in 2014, and delivered full-year operating earnings per share at the high end of our most recent projection," said Aetna chairman and CEO Mark Bertolini. "Our 2014 operating earnings-per-share results represent an increase of more than 7% over 2013 and a compound annualized growth rate of 15% since 2010. We also ended the year serving more than 23.5M medical members, an increase of approximately 1.4M members from 2013." STREET RESEARCH: On March 19, Sterne Agee upgraded Aetna to Buy from Neutral. The firm says that the company is the best-positioned name within the large-cap health plan space, a defensive sector that has little exposure to Europe and reasonable growth prospects, according to the firm. On March 12, Argus increased its price target on Aetna to $115 from $103 after Aetna's Q4 membership growth exceeded its prior targets. The firm said it thinks the company will deliver sustained membership and revenue growth in 2015. It kept a Buy rating on the stock. PRICE ACTION: Aetna shares are up approximately 17% since the company's last earnings report on February 3 and are down over 1% in afternoon trading ahead of Tuesday morning's earnings.
11:02 EDTMDTMedtronic begins clinical study of Endurant Evo AAA strent graft system
Subscribe for More Information
08:04 EDTCNCCentene appoint Ken Yamaguchi to EVP and Chief Medical Officer
Centene announced the appointment of Ken Yamaguchi to Executive Vice President and Chief Medical Officer, effective immediately. Yamaguchi currently is the Sam & Marilyn Fox Distinguished Professor of Orthopaedic Surgery at Washington University and will continue in that role as part-time faculty. Centene also announced the appointment of Mary Mason to Senior Vice President and Chief Medical Officer of Specialty Companies.
April 23, 2015
10:00 EDTSTJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical price target raised to $85 from $77 at Leerink
Subscribe for More Information
06:40 EDTSTJSt. Jude Medical upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
April 22, 2015
08:49 EDTSTJSt. Jude Medical sees FY16 a 'strong year' for neuromodulation segment
Subscribe for More Information
08:31 EDTHUMHumana realigns financial reporting segments
Subscribe for More Information
08:30 EDTSTJSt. Jude Medical sees FY15 CRM constant currency sales down 2% to flat with FY14
Sees FY15 AF product sales growth of 12%-14%. Backs cardiovascular product sales growth view of 6%-8%. Sees neuromodulation products sales growth 13%-15%. Sees acquisition of spinal modulation reducing FY15 EPS by about 5c and accretive to FY16 EPS. Guidance provided during Q1 earnings conference call.
07:18 EDTSTJSt. Jude Medical sees Q2 adjusted EPS 99c-$1.01, consensus 99c
For the second quarter, St. Jude Medical expects revenue to grow in the range of 4%-5% on a constant currency basis compared to the second quarter of 2014 with currency negatively impacting second quarter revenue by approximately $125M-$135M. Revenue consensus is $1.4B.
07:18 EDTSTJSt. Jude Medical sees FY15 adjusted EPS $3.92-$3.97, consensus $3.95
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 total CRM sales $643M, down 6% y/y
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 93c, consensus 91c
Reports Q1 revenue $1.35B, consensus $1.32B.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use